| Latest Zymogenetics News Headlines |
| Date | Time | Source | |
| 10/25/2007 | 6:00AM | PRNUS | ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results
SEATTLE, Oct. 25 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will report third quarter 2007 financial results on Wednesday, October 31, 2007. Members of the company's senior management will discuss the results and provide a general corporate update in a conference call and webcast... More...>> |
| 10/23/2007 | 1:30PM | PRNUS | ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
- Interim data shows promise as a potential treatment for kidney cancer -
SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today presented positive Phase 1 interim data from a Phase 1/2 trial of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) in patients with renal cell cancer... More...>> |
| 10/04/2007 | 6:00AM | PRNUS | ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
- Patient enrollment to begin in fourth quarter -
SEATTLE, Oct. 4 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that, together with its collaborator Merck Serono, it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) to conduct a... More...>> |
| 09/06/2007 | 6:00AM | PRNUS | ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Douglas E. Williams, Ph.D., President and Chief Scientific Officer, will provide an overview of company activities at the Bear Stearns Annual Healthcare Conference on September 10, 2007 at 8:00 a.m. Eastern Time and at the... More...>> |
| 08/22/2007 | 4:05PM | PRNUS | ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that the company will hold a conference call today to provide an update on the regulatory review of recombinant thrombin (rThrombin).
The ZymoGenetics conference call may be accessed on August 22 at 5:00 p.m. Eastern Time by dialing... More...>> |
| 08/01/2007 | 6:00AM | PRNUS | ZymoGenetics Reports Second Quarter 2007 Financial Results
-Partnership with Bayer augments internal preparations for rThrombin launch-
SEATTLE, Aug. 1 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported its financial results for the second quarter ended June 30, 2007. The company reported a net loss for the quarter of $37.3 million, or $0.55 per share... More...>> |
| 07/25/2007 | 6:00AM | PRNUS | ZymoGenetics to Host Conference Call and Webcast on August 1, 2007 to Discuss Q2 2007 Financial Results
SEATTLE, July 25 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will report second quarter 2007 financial results on Wednesday, August 1, 2007 at 6:00 a.m. Eastern Time. The company's senior management will discuss the results and provide a general corporate update in a conference... More...>> |
| 07/02/2007 | 6:00AM | PRNUS | ZymoGenetics Announces Senior Management Promotions
SEATTLE, July 2 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that Douglas E. Williams, Ph.D. has been named President of the company. Bruce L.A. Carter, Ph.D. will continue as ZymoGenetics' Chief Executive Officer and Chairman of the Board. James A. Johnson has been promoted to Executive... More...>> |
| 06/19/2007 | 7:30AM | PRNUS | ZymoGenetics Will Hold Conference Call on June 19 at 8:30 a.m. Eastern Time to Discuss rThrombin Collaboration with Bayer Health
SEATTLE, June 19 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced it will hold a conference call today to discuss the collaboration with Bayer HealthCare to maximize the potential of ZymoGenetics' recombinant human thrombin (rThrombin).
The ZymoGenetics conference call may be accessed on June 19... More...>> |
| 06/19/2007 | 2:01AM | PRNUS | ZymoGenetics Establishes Global Collaboration With Bayer HealthCare for Development and Commercialization of Recombinant Human T
- ZymoGenetics to receive up to $198 million plus royalties, including up to $70 million in 2007 -
SEATTLE, June 19 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today it has entered into multi-year, domestic and global license and collaboration agreements with Bayer HealthCare (NYSE:BAY) to... More...>> |
| 06/04/2007 | 6:00AM | PRNUS | ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
SEATTLE, June 4 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous... More...>> |
| 05/29/2007 | 6:00AM | PRNUS | ZymoGenetics Announces Upcoming Presentations at ASCO
SEATTLE, May 29 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced the upcoming presentation of preliminary results from clinical trials with atacicept in B-cell chronic lymphocytic leukemia and Interleukin 21 (IL-21) in malignant melanoma at the American Society of Clinical Oncology (ASCO) 2007... More...>> |
| 05/17/2007 | 6:00AM | PRNUS | ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences
SEATTLE, May 17 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that company executives will present at the following investor conferences:
James A. Johnson, Senior Vice President and Chief Financial Officer, will present at the Citigroup 2007 Healthcare Conference in New York City on Thursday... More...>> |
| 05/02/2007 | 4:05PM | PRNUS | ZymoGenetics Reports First Quarter 2007 Financial Results
Continuing progress in clinical trials and commercialization preparedness
SEATTLE, May 2 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported its financial results for the first quarter ended March 31, 2007. The company reported a net loss for the quarter of $33.3 million, or $0.49 per share, reflecting... More...>> |
| 05/02/2007 | 4:05PM | PRNUS | ZymoGenetics Reports First Quarter 2007 Financial Results
Continuing progress in clinical trials and commercialization preparedness
SEATTLE, May 2 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported its financial results for the first quarter ended March 31, 2007. The company reported a net loss for the quarter of $33.3 million, or $0.49 per share, reflecting... More...>> |
| 04/26/2007 | 6:00AM | PRNUS | ZymoGenetics to Host Conference Call and Webcast on May 2, 2007 to Discuss Q1 2007 Financial Results
SEATTLE, April 26/PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will report first quarter 2007 financial results on Wednesday, May 2, 2007 after market close. Members of the company's senior management will discuss the results and provide a general corporate update in a conference... More...>> |
| 04/25/2007 | 6:00AM | PRNUS | ZymoGenetics to Webcast Presentation at Morgan Stanley Healthcare Conference
SEATTLE, April 25 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer and Michael J. Dwyer, Senior Vice President, Sales and Marketing will discuss the company's ongoing business activities at the Morgan Stanley... More...>> |
| 03/12/2007 | 7:00AM | PRNUS | ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences
SEATTLE, March 12 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that company executives will present at the following investor conferences:
James A. Johnson, Senior Vice President, Chief Financial Officer and Treasurer, will provide an overview of company activities at the Lehman Brothers... More...>> |
| 03/07/2007 | 6:00AM | PRNUS | ZymoGenetics Provides Update on rhThrombin Development Plans
Phase 3 Clinical Trial Not Required to Gain Approval for rhThrombin Spray
SEATTLE, March 7 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported that the U.S. Food and Drug Administration (FDA) will not require additional clinical trials with recombinant human Thrombin (rhThrombin) administered by... More...>> |
| 02/26/2007 | 12:16PM | PRNUS | ZymoGenetics to Webcast Presentation at RBC Dain Rauscher Northwest Investor Conference
SEATTLE, Feb. 26 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer, will provide an overview of company activities at the RBC Dain Rauscher Northwest Investor Conference in Seattle on Tuesday, February 27... More...>> |